Revolution Medicines’ cyclophilin A–recruiting RAS inhibitor daraxonrasib (Rasonque) keeps dominating the induced-proximity conversation, with new combination data from ESMO 2026 and fresh analysis of its first months on the market. Elsewhere, Novartis has started a second Phase 2 study of Monte Rosa’s VAV1 molecular glue degrader, and this week’s literature brings better AI models of glue ternary complexes and a new antibacterial twist on targeted degradation.
Industry watch
Rasonque settles in as a new standard in pancreatic cancer

Photo: Freestocks.org via StockSnap (CC0)
OncLive, 30 October 2026
A Pancreatic Cancer Awareness Month review recaps the case for daraxonrasib, which the FDA approved in August 2026 for previously treated metastatic pancreatic cancer. In the Phase 3 RASolute 302 trial, median overall survival was 13.2 months versus 6.7 months with chemotherapy, and in October the EMA’s CHMP recommended EU authorisation. As the EMA describes it, daraxonrasib binds cyclophilin A, and the resulting complex binds RAS and blocks its activity. The drug does not degrade RAS. It recruits an abundant intracellular carrier protein to create a new protein–protein interaction. We see this as validation of the approach behind MINIMUM bio’s FKBP-recruiting rapalog molecular glues.
RAS(ON) plus PRMT5 combination posts 82% response rate in MTAP-deleted pancreatic cancer

Image: Scientific Animations Inc. via Wikimedia Commons (CC BY-SA 4.0)
Targeted Oncology, 23 October 2026
At ESMO 2026, Tango Therapeutics reported updated Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with daraxonrasib. In 22 evaluable patients with MTAP-deleted, RAS-mutant pancreatic cancer, the objective response rate was 82%, and a separate cohort tested the combination with zoldonrasib. Tango plans a randomised registrational trial in first-line disease in the first half of 2027. The tri-complex inhibitors are now becoming backbones that other medicines are combined with, a sign of how far carrier-protein glues have come.
Novartis starts second Phase 2 study of Monte Rosa’s VAV1 glue degrader

Image: NIAID via Wikimedia Commons (CC BY 2.0)
Monte Rosa Therapeutics (GlobeNewswire), 28 October 2026
Monte Rosa Therapeutics announced that Novartis has started a second Phase 2 study of MRT-6160 (DDY391), an oral VAV1-directed molecular glue degrader, in moderate to severe psoriatic arthritis. The study follows a Phase 2 study in Sjögren’s disease, and the first patient visit triggers a US$37.5 million milestone payment from Novartis. Molecular glues continue to move beyond oncology into immunology, a field where MINIMUM bio is also building a pipeline.
KRAS inhibitors and CDK degraders feature in September’s patent filings

Image: KRAS G12C with sotorasib (PDB 6OIM), Fvasconcellos via Wikimedia Commons (public domain)
Drug Hunter, 30 October 2026
Drug Hunter’s monthly Patent Gazette highlights 14 programmes across four targets in September 2026 filings, including a new wave of KRAS inhibitors from seven companies, CDK2 and CDK4 degraders, and inhibitors of the SLC15A4–TASL protein–protein interaction. The patent filings show that RAS and protein–protein interfaces remain among the busiest areas for intellectual property.
Research highlights
Sequence Scanning Improves Accuracy for Antibody-Antigen and Molecular Glue Ternary Complex Cofolding
Linker SM, Ploetz T, Evers A et al., ChemMedChem, 2026
Co-folding models such as AlphaFold3 and Boltz-2 are less reliable at predicting molecular glue ternary complexes than most other biomolecular complexes. The authors introduce “sequence scanning”, which applies systematic constraints to diversify sampling in Boltz and Protenix, and report better pose prediction for glues on large benchmark sets. Better structure prediction for glue-mediated complexes is central to AI-driven discovery platforms such as our Phagent AI.
Molecular Glue Degraders of TEM β-Lactamases by Periplasmic Protease DegP
Taylor EK, Santos Barbosa P, Kadambi T et al., Angewandte Chemie International Edition, 2026
The team found that the β-lactamase inhibitor tazobactam speeds the destruction of TEM β-lactamases by the bacterial protease DegP. Adding dipeptide motifs that DegP prefers made the effect stronger. The resulting glue degraders worked better with piperacillin against resistant E. coli than tazobactam did. Induced proximity is now reaching bacterial cells, opening a new mechanism against antimicrobial resistance.
A BromoTag-Based Toolkit for Rapid Modulation of Chemically Induced Proximity
Colombo GM, Kim D, Hassan MM et al., ACS Chemical Biology, 2026
The authors built homo- and hetero-bivalent BromoTag and dTAG ligands that induce new protein–protein interactions between engineered domains. They measured activity with a split-luciferase assay and showed caspase-9 and c-Kit activation comparable to established dimeriser systems. Classic FKBP-based dimerisers launched the field, and this toolkit adds a complementary option for prototyping non-degrading proximity biology.
PROTAC-DB 4.0: an expanded knowledgebase of targeted protein degradation modalities with AI-powered knowledge discovery
Ge J, Yin C, Li Y et al., Nucleic Acids Research, 2026
The latest release of this widely used database holds more than 15,000 PROTAC entries, almost 25,000 molecular glue entries and 272 entries for other chimera formats, with richer experimental and patent annotation. Users can now ask questions in plain English through a large language model that links database records to the literature. It is a valuable open resource for data-driven glue and degrader design.
If you are working on induced-proximity therapeutics and would like to partner or invest, we would love to hear from you: get in touch with MINIMUM bio.